U.S. stocks edged higher Wednesday morning, recovering slightly from this week’s selloff as Commerce Secretary Howard Lutnick ...

If passed, anyone who provides or administers a gene-based vaccine to another person would face a penalty of $500 per violation.

Johns Hopkins Medicine laboratory scientists say they have developed a potential new way to treat a variety of rare genetic ...

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...

The FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.

A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna .

The vaccine space has been battered by strong headwinds in recent weeks, including high-level disruptions to FDA and CDC ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

With U.S. stock markets set to open in two hours, Huntington Ingalls Industries Inc. (HII) was up 11.5% in pre-market trading, and Moderna Inc. (MRNA) was up 9.1%.

A bill banning gene-based vaccines, like some forms of the COVID-19 vaccine, received approval from a Senate subcommittee ...

Boosting cells with a tardigrade protein reduced DNA damage after radiation, offering potential protection for healthy tissue ...

Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...